SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Tenet Healthcare Corporation (THC) trades at a trailing P/E of 12.6, forward P/E of 11.5. Trailing earnings yield is 7.94%, forward earnings yield 8.73%. PEG 1.06. Graham Number is $191.71.
Criteria proven by this page:
- VALUE (49/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 11.5 (down from trailing 12.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.06 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 7.94% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.73% as earnings recover.
- Analyst consensus target $258.55 (+31.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 69/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
49/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — THC
Valuation Multiples
P/E (TTM)12.6
Forward P/E11.5
PEG Ratio1.06
Forward PEG1.06
P/B Ratio4.20
P/S Ratio0.83
EV/EBITDA6.3
Per Share Data
EPS (TTM)$16.00
Forward EPS (Est.)$17.16
Book Value / Share$102.06
Revenue / Share$242.39
FCF / Share$28.78
Yields & Fair Value
Earnings Yield7.94%
Forward Earnings Yield8.73%
Dividend Yield0.00%
Graham Number$191.71
SharesGrow IV$535.37 (+172.3%)
Analyst Target$258.55 (+31.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-7.7 |
-0.21 |
3.53 |
0.08 |
- |
| 2017 |
-2.2 |
-0.01 |
-10.37 |
0.08 |
- |
| 2018 |
16.8 |
-0.15 |
-14.71 |
0.10 |
- |
| 2019 |
-18.3 |
0.06 |
-10.60 |
0.21 |
- |
| 2020 |
10.5 |
-0.04 |
149.75 |
0.24 |
- |
| 2021 |
9.5 |
0.08 |
8.49 |
0.45 |
- |
| 2022 |
12.7 |
-0.23 |
4.57 |
0.27 |
- |
| 2023 |
12.6 |
0.22 |
4.78 |
0.37 |
- |
| 2024 |
3.8 |
0.01 |
2.93 |
0.59 |
- |
| 2025 |
12.8 |
-0.24 |
4.28 |
0.85 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.93 |
$19.62B |
$-192M |
-1% |
| 2017 |
$-7.00 |
$19.18B |
$-704M |
-3.7% |
| 2018 |
$1.07 |
$18.31B |
$111M |
0.6% |
| 2019 |
$1.38 |
$18.48B |
$143M |
0.8% |
| 2020 |
$7.23 |
$17.64B |
$768M |
4.4% |
| 2021 |
$13.60 |
$19.49B |
$1.48B |
7.6% |
| 2022 |
$9.05 |
$19.17B |
$1B |
5.2% |
| 2023 |
$5.71 |
$20.55B |
$611M |
3% |
| 2024 |
$32.70 |
$20.67B |
$3.2B |
15.5% |
| 2025 |
$15.49 |
$21.31B |
$1.41B |
6.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$17.16 |
$16.58 – $18.06 |
$22.02B |
$21.93B – $22.2B |
12 |
| 2027 |
$17.56 |
$15.32 – $20.52 |
$22.42B |
$21.95B – $22.8B |
12 |
| 2028 |
$19.99 |
$16.13 – $22.12 |
$23.7B |
$23.69B – $23.7B |
4 |
| 2029 |
$23.74 |
$23.20 – $24.30 |
$23.78B |
$23.36B – $24.21B |
2 |
